Microsoft Reportedly Plans New Job Cuts Across Sales, Consulting, and Xbox 
U.S. Stocks End Q2 Higher as Strong Jobs Data and AI Rally Lift Wall Street 
RBA Minutes Signal Australia Central Bank Remains Ready to Raise Interest Rates if Inflation Persists 
Anthropic Restores Claude Fable 5 and Mythos 5 After U.S. Lifts AI Export Controls 
Nike Q4 Earnings Beat Estimates as Wholesale Growth Offsets Direct Sales Weakness 
Trump Suspends Some Morocco Fertilizer Tariffs to Ease U.S. Supply Shortage 
Chip Stocks Rally as Samsung and SK Hynix’s $1.3 Trillion Investment Plan Boosts AI Optimism 
Economic pessimism has set in – but there are reasons for Australians to be hopeful 
Oil Prices Rise as U.S.-Iran Talks Keep Geopolitical Risks in Focus 
Trump Urges Gasoline Retailers to Cut Prices to $2.50 Per Gallon, Warns of Legal Action 
Asian Currencies Slip as Dollar Holds Firm, Yen Near Four-Decade Low Ahead of Fed, Jobs Data 
Greece’s Bad Loan Crisis Continues to Limit Credit Access Despite Economic Recovery 
NATO Albania Summit Faces Uncertainty as Trump, Defense Spending Concerns Loom 
Global Financial Firms Shift Asia Expansion Focus to South Korea as China, India Face Caution 
Australia Sues Amazon Over Prime Video Ads and Subscription Terms 
Gold Prices Drop as Fed Rate Outlook and Iran Tensions Weigh on Market 
Argentina Economy Shrinks 1.5% in April, Recovery Under Milei Loses Momentum 
Bausch + Lomb announces a $1.75 billion definitive agreement with Novartis to acquire XIIDRA dry eye treatment, positioning the Ontario-based eye health company as a leader in ocular surface diseases and bolstering its prescription dry eye unit.
With the purchase, Bausch + Lomb will have a considerable opportunity to grow its prescription dry eye unit further. Novartis AG is divesting its XIIDRA dry-eye treatment to the Swiss drugmaker, and the transaction value could go up to $2.5 billion with a $1.75 billion upfront payment.
In any case, Novartis acquired the XIIDRA product from Takeda for $3.4 billion in 2019. Pharmastar reported that under the helm of leadership of chief executive officer Vas Narasimhan, Novartis has been expanding the company by spinning off some of the low-growth business units, such as its Alcon eye care. It has plans to do the same for its Sandoz healthcare company subsidiary.
“This acquisition is a prime example of our strategy in action, as it provides needed scale for the company and transforms our pharmaceuticals business by making us a leader in ocular surface diseases,” Bausch + Lomb’s chairman and CEO, Brent Saunders, said in a press release. “The deal is also expected to accelerate margin expansion through a larger mix of pharmaceutical products in our portfolio, provide strong and immediate earnings accretion and presents a clear path to deleverage, making it financially compelling.”
Marguerite McDonald, M.D., F.A.C.S., OCLI Vision at Oceanside, N.Y., also explained that “Dry eye disease is multi-factorial and can stem from varying root causes, which means differing treatment options are needed. With the acquisition of XIIDRA and the recent approval of MIEBO, Bausch + Lomb enhances its approach to different facets of dry eye and is well positioned to ensure both medicines reach as many patients as possible.”
Photo by: Bausch & Lomb Website
